Critical care demand and intensive care supply for patients in Japan with COVID-19 at the

time of the state of emergency declaration in April 2020: a descriptive analysis.

Yosuke Fujii, MD[1, 2, *], and Kiichi Hirota, MD, PhD[2].

1. Department of Anesthesia, Otsu City Hospital, Shiga, Japan.

2. Department of Human Stress Response Science, Institute of Biomedical Science, Kansai

Medical University, Osaka, Japan.

*corresponding author

Yosuke Fujii

Department of Human Stress Response Science, Institute of Biomedical Science, Kansai

Medical University, Hirakata, Osaka, Japan

phone: +81-72-804-2526

email: yofujii-kyt@umin.ac.jp

Keywords: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); The

coronavirus disease 2019 (COVID-19); intensive care unit (ICU); extracorporeal membrane

oxygenation (ECMO).

Abstract

Background: The coronavirus disease 2019 (COVID-19) pandemic, due to severe acute

respiratory syndrome coronavirus 2 (SARS-CoV-2), threatened to overwhelm Japan's

intensive care capacity due to the rising numbers of infected patients. This study aimed to

determine the number of critically ill patients with COVID-19 who required intensive care,

including mechanical ventilation and extracorporeal membrane oxygenation (ECMO),

during the pandemic and to compare these patient numbers with Japan's overall intensive

care capacity.

Methods: Japanese Society of Intensive Care Medicine datasets were used to obtain the

number of confirmed patients with COVID-19 who had undergone mechanical ventilation

and ECMO between February 15 and June 4 2020, to determine and compare intensive care

unit (ICU) and attending bed needs for patients with COVID-19, and to estimate peak ICU

demands in Japan.

Results: In total, 17968 ICU days, 15171 mechanical ventilation days, and 2797 ECMO

days were attributable to patients with COVID-19. There was a median (interquartile range)

143 (63-255) patients in ICU, 124 (51-225) patients on mechanical ventilation, and 18 (15-

36) patients on ECMO machines. During the epidemic peak in late April, 11443 patients

(1.03 per 10000 adults) had been infected, 373 patients (0.034 per 10000 adults) were in

ICU, 312 patients (0.028 per 10000 adults) were receiving mechanical ventilation, and 62

patients (0.0056 per 10000 adults) were on ECMO machines per day. The number of

infected patients at the peak of the epidemic was 651% of total designated beds and the

number of patients requiring intensive care at the peak of the epidemic was 6.0% of total

ICU beds in Japan, 19.1% of total board-certified intensivists in Japan and 106% of total

designated medical institutions for Category II infectious diseases in Japan, respectively.

Conclusions: Following the state of emergency declaration on April 7 2020, the number of

patients with COVID-19 and the number of critically ill patients continued to rise,

exceeding the number of designated beds but not exceeding ICU capacity. Urgent

nationwide and regional planning is needed to prevent an overwhelming burden on ICUs in

relation to critically ill patients with COVID-19 in Japan.

Introduction

A novel coronavirus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China, in December 2019, and the number of newly reported cases has continued to increase globally. As at June 4 2020, >6.2 million cases had been reported worldwide and >300000 people had died [1], with 17000 Reported cases and nine deaths recorded in Japan. On January 30 2020, the World Health Organization (WHO) declared the epidemic to be a "public health emergency of international concern". On April 7 2020, Japan declared a state of emergency in seven major central cities, which then was extended to all 47 prefectures on April 16 2020 [2].

COVID-19 affects the respiratory system and patients infected with SARS-CoV-2 suffer from respiratory syndromes [3]. Although approximately 70-80% of patients with COVID-19 have mild to moderate symptoms and recover, 5-20% of patients develop severe respiratory failure and may require admission to an intensive care unit (ICU) [3-5]. Symptomatic treatment for severe respiratory failure has involved the use of mechanical ventilation and extracorporeal membrane oxygenation (ECMO) [5-9] as there are currently no specific drugs or other procedures available to treat patients with COVID-19. One study that analyzed clinical cases of COVID-19 reported a better prognosis in patients with mild infection, whereas the prognosis for patients with severe and critical infections is poor. However, patients presenting with mild infection are less obvious and are less easily located or identified [10]. A previous observational study reported that approximately 50% of the patients admitted to ICU required ventilation support and, of these, one in four patients required considerably greater levels of intensive life support [10]. A cohort study

found approximately 8% of patients with COVID-19 were critically ill [11]. One case series

reported that, of 18 patients who required intubation, 1 patient required ECMO and 5

patients died [12]. It has been estimated that, despite intensive life support, approximately

3-4% of all infected patients are likely to die due to SARS-CoV-2 infection [3,13].

The importance of ICUs during the COVID-19 pandemic has been well established;

however, ICU capacity in relation to expected numbers of patients with COVID-19

requiring intensive care is unknown. During the COVID-19 epidemic, there has been a

dramatic surge in the number of critically ill patients with an urgent need for ICU

admission [14], as occurred in other natural disasters [15,16]. An analysis of the epidemic

peak in Wuhan indicated that the number of severely and critically ill adult patients

requiring intensive care was estimated to be 12.2/10000 and 2.6/10000, respectively [17].

However, this situation clearly differs between countries, and specific data sourced in terms

of Japanese circumstances are needed [18]. This study aimed to determine the number of

critically ill patients who required ICU admission, including the number of patients

requiring mechanical ventilation and ECMO, and to compare these patient numbers with

ICU capacity in Japan at nationwide and regional levels.

Methods

Ethical approval

Institutional Review Board approval and patient informed consent were not required for

this study, as this study did not involve human participant research or any interventions.

Permission to use the data and analysis was obtained from the Japanese Society of Intensive

Care Medicine (JSICM) [19].

Infectious disease data source

We obtained data concerning numbers of infected, recovered, and dead patients due to

COVID-19 in Japan from a publicly available website [20]. The number of patients who

required mechanical ventilation and ECMO support was extracted from the JSICM website

[18,19]. This database accumulates data using a CRoss Icu Searchable Information System

(CRISIS). More than 570 facilities across Japan currently participate in this CRISIS,

centering on facilities certified by the JSICM and facilities designated by the Japanese

Society of Emergency Medicine, with a total of 5500 ICU beds, covering 80% of the total

ICU beds in Japan [21]. This database provides information concerning the number of

patients under mechanical ventilation, under ECMO, the number of patients in recovery

from ECMO, and the number of patients who died during ECMO.

Intensive care unit capacity data source

We extracted the number of ICU beds (n = 7109) and board-certified intensivists (n = 1957)

from the JSICM website. This website has also reported the estimated number of

mechanical ventilators for adults (n = 30091) and ECMO machines (n = 2208) in Japan

(Table 1) [22].

In Japan, COVID-19 was designated as an infectious disease under the Infectious Diseases

Control Law on January 28 2020. Patients with COVID-19 were admitted and transferred

to designated medical institutions responsible for the hospitalization of patients with a

Category II infectious disease (especially tuberculosis) or a novel influenza infection.

Although clear evidence of person-to-person airborne transmission of SARS-CoV-2 has not

been established, an airborne component of transmission is likely, based on other

respiratory viruses such as severe acute respiratory syndrome (SARS), Middle East

respiratory syndrome (MERS), and influenza [23-26] and its presence in aerosol has been

confirmed at RNA level [27,28]. Many infectious control guidelines recommend that

healthcare workers be protected through the use of personal protective equipment [29-31].

Suspicious airborne infectious routes make patient care difficult and complex, requiring the

management of the patient using airborne precautions [32] or management of the patient in

a depressurized area [31]. A patient management ratio of one critically ill patient to one

depressurized area per hospital has been used, assuming that not all infected patients could

be treated in ICU beds. In Japan, there are 1758 beds designated for patients with a

Category II infectious disease, 3502 beds allocated for patients with tuberculosis, and 351

designated medical institutions for patients with Category II infectious diseases (table 1)

[33].

ECMO is a highly integrated critical care treatment that requires multidisciplinary team

collaboration [34,35]. It is also assumed that not all of the ECMO machines in Japan could

be allocated to manage critically ill patients with COVID-19. In Japan, an organized

ECMO-based respiratory program, namely, the ECMO project [36], comprises a

consortium of specialized institutions for ECMO involving the participation of 100

hospitals in this project. We assumed these hospitals were the institutions specially

dedicated to treat critically ill patients with COVID-19 who required treatment using

ECMO machines (table 1) [36].

Board-certified intensivists and patient numbers in ICUs in seven regions in Japan

according to the JSICM and CRISIS

Data concerning population numbers in Japan in 2019 at nationwide and regional levels and

the proportion of adults aged ≥15 years were retrieved from the Statistics Bureau of Japan

[37]. The national population was 1.26×10^8 and the proportion of adults was 87.9%. To

determine regional differences, we analyzed the demand and supply of ICUs in the 47

prefectures. The JSICM and CRISIS have reported the number of board-certified

intensivists and the number of patients in ICU in seven regions in Japan, namely, Hokkaido,

Tohoku, Kanto-Koshinetsu, Tokai-Hokuriku, Kansai, Chugoku-Shikoku, and Kyusyu-

Okinawa (figure 1). Data concerning the 47 prefectures were then integrated according to

these seven regions (table 1).

Statistical analysis

The total number of patient days in ICU was summed to estimate the total number of ICU

days and the raw number of patients in ICU on each day was plotted [17]. The notation

"ICU" denoted the total number of patients on mechanical ventilator and ECMO. The

proportion of critically ill patients per 10000 adults was estimated based on the number

presented in the infectious diseases and ICU capacity data source sections.

Results

COVID-19 accounted for a total of 17968 ICU days, 15171 mechanical ventilation days,

and 2797 ECMO days between January 15 2020 and June 4 2020, with a median

(interquartile range [IQR]) of 143 (63-255) patients in ICU, 124 (51-225) patients on

mechanical ventilation, and 18 (15-36) patients on ECMO machines each day during this

111-day period (Figure 2, Table 2). During the peak of the epidemic in late April 2020,

11443 patients (1.03 per 10000 adults) had been infected with SARS-CoV-2 and, of these,

373 patients (0.034 per 10000 adults) were admitted to ICU, 312 patients (0.028 per 10000

adults) were treated using mechanical ventilation, and 62 patients (0.0056 per 10000 adults)

were treated using ECMO machines per day.

The number of infected patients at the peak of the epidemic was 651% of total designated

beds for Category II infectious disease and 218% of total Category II with tuberculosis beds,

and the number of patients requiring intensive care at the peak of the epidemic was 6.0% of

total ICU beds in Japan, 19.1% of total board-certified intensivists in Japan, and 106% of

total Category II institutions. The number of patients requiring ECMO at the peak of the

epidemic was 3.2% of total board-certified intensivists in Japan, 17.7% of total Category II

institutions, and 62% of total hospitals participating in ECMO project in Japan, respectively

(figure 2 and table 3).

The number of total ICU days was 1307 (IQR, 7-11) in Hokkaido, 168 (0-3) days in

Tohoku, 9741 (40-127) days in Kanto-Koshinetsu, 1044 (6-14) days in Tokai-Hokuriku,

4227 (8-65) days in Kansai, 302 (0-5) days in Chugoku-Shikoku, and 1179 (0-20) days in

Kyusyu-Okinawa (figure 3 and table 2).

ICU demand compared with the proportion of board-certified intensivists greatly increased

in Hokkaido (37.3% of total board-certified intensivists in Hokkaido), in Kanto-Koshinetsu

(26.7%), and in Kansai (27.7%) compared with the overall demand in Japan (19.1%). ICU

and mechanical ventilation demand overwhelmed the number of Category II institutions in

Hokkaido (117% of total Category II institutions of ICU and 108% of total Category II

institutions for mechanical ventilation), in Kanto-Koshinetsu (213% for ICU and 176% for

mechanical ventilation), and in Kansai (262% for ICU and 241% for mechanical

ventilation) (table 3). The number of patients requiring ECMO compared with the number

of ECMO project hospitals was 125% in Hokkaido and a 106% in Kanto-Koshinetsu

(figure 4 and table 3).

Discussion

The number of new patients diagnosed with COVID-19 continues to increase globally.

Approximately 70-80% of patients infected with SARS-CoV-2 show mild to moderate

respiratory symptoms; however, between 5% and 32% of these patients may develop severe

symptoms and require ICU admission, of whom between 3% and 22% may require

mechanical ventilation and between 0.5% and 5% may require oxygenation with ECMO

[3,4,10,32,38-40]. Depending on the efficacy of infection control strategies, a shortage of

ICU ventilators may or may not eventuate [41].

Exceeding hospital bed capacity would likely increase the community spread of SARS-

CoV-2 and lead to decreased quality of healthcare and intensive care [17]. In China,

national lockdown, quarantine, and social distancing measures were adopted to control the

spread of infection, with >10000 beds designated for the isolation and treatment of patients

with confirmed COVID-19 by early February, 2020 [17]. Despite these efforts to control

the spread of infection, this did not lead to an immediate downturn in demand for

hospitalization in critical care units and in ICUs in China [17], and this situation has been

similar in Japan.

Our results indicated a critical need to isolate and treat patients with COVID-19; however,

while there remained a small margin for critically ill patients requiring mechanical

ventilation and ECMO in terms of ICU capacity, this situation was sub-optimal. Intensivists

do not necessarily attend to all critically ill patients, and have been reported to provide care

to only 37% of all ICU patients [42]. In the United States, one study reported that only

approximately 30% of intensive care units were staffed by dedicated intensivists [43]. We

have assumed that these percentages are likely to be the same or no greater in Japan. The

number of critically ill patients in ICU at the peak of the epidemic accounted for 19% of

total board-certified intensivists in Japan, which challenged Japan's ICU capacity.

Our findings also showed a regional bias in terms of ICUs being overwhelmed in Japan.

Kanto-Koshinetsu and Kansai are the biggest regions in Japan. The Kanto-Koshinetsu

region includes Japan's capital city, Tokyo, which is the most populous prefecture and also

includes Kanagawa, which is the second most populous prefecture. The Kansai region

includes Osaka, which is the third most populous prefecture. A large population and the

movement of people to and from these regions is thought to have spread the infection,

which resulted in medical capacity becoming overwhelmed. Hokkaido, the largest

prefecture in Japan, had an increase in the number of patients with COVID-19 in the early

phase of the epidemic. Epidemiological evidence to explain this phenomenon remains

limited. Prior to the administration's state of emergency declaration, the local government

in Hokkaido issued its own emergency declaration on February 28 2020 in an effort to

control the spread of infection [44].

ECMO management in Japanese hospitals has previously resulted in poorer outcomes [45]

compared with those reported in other countries during the N1H1 influenza epidemic

[34,46-50]. There is wide consensus that ECMO treatment should be performed at centers

with high case volumes and established protocols, and involving clinicians who are

experienced in its use. Patients who require ECMO treatment should be transferred to

appropriate ECMO centers [34,35,45,50]. Japan has introduced an ECMO project [36] and

the ECMOnet [18,19], which involve a consortium working to promote the appropriate use

of ECMO, to help develop an evidence-based foundation for its use, to strive for continued

improvement in its application where appropriate, and to collect data concerning the

number of patients requiring mechanical ventilation and ECMO support [51,52]. There are

>2000 ECMO machines available for use in Japan. The number of patients requiring

ECMO was 3.2% of all ECMO machines at the peak of the epidemic, but the capacity

levels in terms of use should not be overestimated. In terms of the hospitals participating in

the ECMO project in Japan, the number of patients requiring ECMO was 62% of their

work at the peak of epidemic, which is likely to provide a more realistic estimate of their

intensive care capacity.

Our study had several limitations. First, the number of critically ill patients requiring

intensive care was not completely addressed in the JSICM database. This database has been

estimated to capture >80% of clinical cases [19,21]; however, it relies heavily on the

cooperation of physicians struggling to treat large numbers of critically ill patients.

Second, the extent of the ICU capacity was not completely validated nor was the number of

patients requiring admission to ICUs. The JSICM reported the estimated number of

ventilators and ECMO machines according to responses to a questionnaire sent to its

member hospitals. Therefore, there was risk of overestimating ICU capacity. Third, the

assumption of one critically ill patient to one depressurized area per hospital did not

necessarily reflect the real life situation. For example, one author's institution was

designated as a Category II infectious diseases institution with eight ICU beds, one

depressurized area, and six Category II beds, with one board-certified intensivist. This

institution was not a member of the ECMO project. Six Category II beds were fully

occupied as soon as the number of infected patients threatened to overwhelm the capacity

of the ICU, and other wards were then rearranged to manage patients with mild

manifestations of COVID-19. There were two alternatives to treat critically ill patients with

COVID-19: one was to use an ICU depressurized bed, and the other was to rearrange the

beds in the emergency department. The latter option was chosen because other critically ill

and surgical patients could not be treated in the ICU when occupied by patients with

COVID-19 for fear of airborne transmissions. Most hospitals are thought to have flexibly

employed a variety of methods to increase their capacity to treat patients with COVID-19.

Conclusion

During the COVID-19 pandemic and following the state of emergency declaration in Japan,

the number of patients threatened to overwhelm the number of beds designated for

infectious patients; however, Japan's ICU capacity was sufficient to withstand the demands

for mechanical ventilation and ECMO. However, there is no room for complacency in this

situation. Urgent consideration is needed in relation to future planning concerning how to

mitigate the threat to providing intensive care for critically ill patients with COVID-19 at

domestic and regional levels in Japan.

Figure 1: Seven regions in Japan defined by The Japanese Society of Intensive Care

Medicine. Seven regions are Hokkaido, Tohoku (Aomori, Iwate, Akita, Miyagi, Yamagata,

and Fukushima), Kanto-Koshinetsu (Ibaraki, Tochigi, Gumma, Saitama, Chiba, Tokyo,

Kanagawa, Niigata, Yamanashi, and Nagano), Tokai-Hokuriku (Toyama, Ishikawa, Fukui,

Gifu, Shizuoka, Aichi, and Mie), Kansai (Shiga, Kyoto, Osaka, Hyogo, Nara, and

Wakayama), Chugoku-Shikoku (Tottori, Shimane, Okayama, Hiroshima, Yamaguchi,

Tokushima, Kagawa, Ehime, and Kochi), and Kyushu-Okinawa (Fukuoka, Saga, Nagasaki,

Kumamoto, Oita, Miyazaki, Kagoshima, and Okinawa).

Figure 2: Burden of critical coronavirus disease during epidemic in Japan. (A) The number

of infected and critically ill patients per 1000 adults. Critically ill patients were the sum of

the number of the patients under mechanical ventilation and ECMO. Japanese government

also declared "The State of Emergency" on 7 April 2020 for major central cities with a

cumulative 4257 confirmed cases and 93 deaths among patients with COVID-19 and it

spread to all of 47 prefectures on 16 April 2020. (B) The magnified version of figure A.

Category II; designated medical institutions for Category II infectious diseases, TB;

tuberculosis, ECMO; extracorporeal membrane oxygenation.

Figure 3: Burden of critical coronavirus disease during epidemic in seven regions defined

by the Japanese Society of Intensive Care Medicine in Japan. Raw count of COVID-19

patients under critical care (A), mechanical ventilation (B), and ECMO (C), percentage of

patients to the number of board-certified intensivist for critical care (D), mechanical

ventilation (E), and ECMO (F), and percentage of patients to the number of Category II

institutions for critical care (G), mechanical ventilation (H), and ECMO (I), respectively.

Category II; designated medical institutions for Category II infectious diseases, ECMO;

extracorporeal membrane oxygenation.

Figure 4: Burden of critical coronavirus disease requiring ECMO to the number of ECMO

project hospital during epidemic in seven regions defined by the Japanese Society of

Intensive Care Medicine in Japan. ECMO; extracorporeal membrane oxygenation.

	Hokkaido	Tohoku	Kanto-Koshinetsu	Tokai-Hokuriku	Kansai	Chugoku-Shikoku	Kyusyu-Okinawa	Japan
Prefecture	1	6	10	7	6	9	8	47
Population (10^5 adult)	468.5	769.8	4287	1565.3	1805.4	966.6	1233.4	11075.4
Category II beds	92 (0.02)	171 (0.022)	531 (0.012)	220 (0.014)	238 (0.013)	206 (0.021)	300 (0.024)	1758 (0.016)
Category II + TB beds	153 (0.033)	261 (0.034)	937 (0.022)	513 (0.033)	616 (0.034)	397 (0.041)	625 (0.051)	3502 (0.032)
Intensivist	75 (0.016)	95 (0.012)	727 (0.017)	233 (0.015)	368 (0.02)	228 (0.024)	231 (0.019)	1957 (0.018)
Category II institution	24 (0.005)	40 (0.005)	91 (0.002)	46 (0.003)	39 (0.002)	42 (0.004)	69 (0.006)	351 (0.003)
ECMO project hospital*	4 (0.0085)	8 (0.0104)	35 (0.0082)	11 (0.007)	24 (0.0133)	6 (0.0062)	12 (0.0097)	100 (0.009)

313   Table 1: Critical care capacity in Japan and seven regions. The raw count and the

314   proportional count per 10000 adults in parenthesis were listed. *: 100000 adults. Category

315   II; designated medical institutions for Category II infectious diseases, TB; tuberculosis,

316   ECMO; extracorporeal membrane oxygenation.

	Hokkaido	Tohoku	Kanto-Koshinetsu	Tokai-Hokuriku	Kansai	Chugoku-Shikoku	Kyusyu-Okinawa	Japan
ICU	1307 [7, 11, 17]	168 [0, 1, 3]	9741 [40, 85, 127]	1044 [6, 9, 14]	4227 [8, 28, 65]	302 [0, 2, 5]	1179 [0, 12, 20]	17968 [63, 143, 255]
ventilation	1123 [5, 8, 16]	138 [0, 1, 2]	7987 [30, 72, 110]	885 [6, 8, 12]	3835 [8, 26, 59]	293 [0, 2, 5]	910 [0, 10, 15]	15171 [51, 124, 225]
ECMO	184 [1, 2, 2]	30 [0, 0, 1]	1754 [10, 13, 20]	159 [1, 1, 2]	392 [0, 4, 6]	9 [0, 0, 0]	269 [0, 2, 5]	2797 [15, 18, 36]

317   Table 2: ICU -, ventilation-, and ECMO-day for seven regions and Japan. The total days

318   and 0.25, 0.5, and 0.75 quartile days in brackets were shown. ICU; intensive care unit,

319   ECMO; extracorporeal membrane oxygenation.

	Hokkaido	Tohoku	Kanto-Koshinetsu	Tokai-Hokuriku	Kansai	Chugoku-Shikoku	Kyusyu-Okinawa	Japan
Intensivist								
ICU	37.3	5.3	26.7	8.6	27.7	3.9	13	19.1
ventilation	34.7	4.2	22	6.4	25.5	3.5	10	15.9
ECMO	6.7	1.1	5.1	2.1	3	0.4	3.5	3.2
Category II institution								
ICU	116.7	12.5	213.2	43.5	261.5	21.4	43.5	106.3
ventilation	108.3	10	175.8	32.6	241	19	33.3	88.9
ECMO	20.8	2.5	40.7	10.9	28.2	2.4	11.6	17.7
ECMO project								
ECMO	125	12.5	105.7	45.5	45.8	16.7	66.7	62

Table 3: The percentage of the number of patients requiring critical care, mechanical

ventilation, and ECMO to the number of board-certified intensivists, Category II

institutions, and ECMO project hospitals for each region in Japan at the peak of epidemic.

ICU; intensive care unit, Category II; designated medical institution for Category II

infectious diseases, TB; tuberculosis, ECMO; extracorporeal membrane oxygenation.

Abbreviations

WHO: World Health Organization; ECMO: Extracorporeal membranous oxygenation;

COVID-19: Coronavirus induced disease 2019; JSICM: the Japanese Society of Intensive

Care Medicine; IQR: interquartile range.

Authors' contributions

YF and KH drafted the manuscript. YF analyzed the data. The author(s) read and approved

the final manuscript.

Funding

This work was supported by the branding program as a world-leading research university

on intractable immune and allergic diseases from MEXT Japan to K.H.

Acknowledgement

The authors appreciate the permission of use of data from the Japanese Society of Intensive

Care Medicine. The authors would like to thank Editage (www.editage.com) for English

language editing.

Availability of data and materials

The datasets used and analyzed during the current study are available from the

corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

All authors report no conflicts of interest to declare.

References

1.   World Health Organization, Available at

https://www.who.int/emergencies/diseases/novel-coronavirus-2019 .

2.   COVID-19 Information and Resouces, Available at https://corona.go.jp/en/ .

3.   Fu, L. et al., Clinical characteristics of coronavirus disease 2019 (COVID-19) in

China: A systematic review and meta-analysis. Journal of Infection (2020).

4.   Chen, N. et al., Epidemiological and clinical characteristics of 99 cases of 2019

novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395

(10223), 507-513 (2020).

5.   Hong, X., Xiong, J., Feng, Z. & Shi, Y., in International Journal of Infectious

Diseases (Elsevier B.V., 2020), Vol. 94, pp. 78-80.

6.   Firstenberg, M. S. et al., Successful COVID-19 rescue therapy by extra-corporeal

membrane oxygenation (ECMO) for respiratory failure: a case report. Patient safety in

surgery 14, 20 (2020).

7.   Taniguchi, H. et al., Veno‑venous extracorporeal membrane oxygenation for

severe pneumonia: COVID‑19 case in Japan. Acute Medicine & Surgery 7 (1) (2020).

8.   Maclaren, G., Fisher, D. & Brodie, D., in JAMA - Journal of the American Medical

Association (American Medical Association, 2020), Vol. 323, pp. 1245-1246.

9.   Hartman, M. E. et al., COVID-19 Respiratory Failure. ASAIO Journal, 1 (2020).

10.   Wang, D. et al., Clinical Characteristics of 138 Hospitalized Patients with 2019

Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - Journal of the American

Medical Association 323 (11), 1061-1069 (2020).

11.   Liang, W. et al., Development and Validation of a Clinical Risk Score to Predict the

Occurrence of Critical Illness in Hospitalized Patients With COVID-19. JAMA internal

medicine (2020).

12.   Wang, J., Lu, F., Zhou, M., Qi, Z. & Chen, Z., [Tracheal intubation in patients with

severe and critical COVID-19: analysis of 18 cases]. Nan fang yi ke da xue xue bao =

Journal of Southern Medical University 40 (3), 337-341 (2020).

13.   Sun, P. et al., Clinical characteristics of hospitalized patients with SARS‑CoV‑2

infection: A single arm meta‑analysis. Journal of Medical Virology 92 (6), 612-617

(2020).

14.   Qiu, H. et al., in Intensive Care Medicine (Springer, 2020), Vol. 46, pp. 576-578.

15.   Devereaux, A., Christian, M. D., Dichter, J. R., Geiling, J. A. & Rubinson, L.,

Summary of suggestions from the Task Force for Mass Critical Care Summit, January 26-

27, 2007, presented at Chest, 2008 (unpublished).

16.   Rubinson, L. et al., Definitive care for the critically III during a disaster: Medical

resources for surge capacity, presented at Chest, 2008 (unpublished).

17.   Li, R. et al., Estimated Demand for US Hospital Inpatient and Intensive Care Unit

Beds for Patients With COVID-19 Based on Comparisons With Wuhan and Guangzhou,

China. JAMA network open 3 (5), e208297 (2020).

18.   Shime, N., Save the ICU and save lives during the COVID-19 pandemic. Journal of

Intensive Care 2020 8:1 8 (1), 1-3 (2020).

19.   The Japanese Society of Intensive Care Medicine, ECMOnet, Available at

https://crisis.ecmonet.jp/.

20.   worldmeter, Available at https://www.worldometers.info/coronavirus/country/japan/.

21.   https://www.covid19-jma-medical-expert-meeting.jp/, Available at

https://www.covid19-jma-medical-expert-meeting.jp/topic/1121.

22.   Estimate of the number of ventilator, etc, in Japanese hospitals, Available at

https://www.jsicm.org/news/upload/jsicm_info_ventilator_200514.pdf.

23.   Setti, L. et al., in International Journal of Environmental Research and Public Health

(MDPI AG, 2020), Vol. 17.

24.   Anderson, E. L., Turnham, P., Griffin, J. R. & Clarke, C. C., in Risk Analysis

(Blackwell Publishing Inc., 2020), Vol. 40.

25.   Morawska, L. & Cao, J., in Environment International (Elsevier Ltd, 2020), Vol.

139.

26.   Wilson, N. M., Norton, A., Young, F. P. & Collins, D. W., in Anaesthesia

(Blackwell Publishing Ltd, 2020).

27.   Liu, Y. et al., Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals.

Nature (2020).

28.   Wang, J. et al., SARS-CoV-2 RNA detection of hospital isolation wards hygiene

monitoring during the Coronavirus Disease 2019 outbreak in a Chinese hospital.

International Journal of Infectious Diseases 94, 103-106 (2020).

29.   Wax, R. S. & Christian, M. D., in Canadian Journal of Anesthesia (Springer, 2020),

Vol. 67, pp. 568-576.

30.   Ferioli, M. et al., Protecting healthcare workers from sars-cov-2 infection: Practical

indications. European Respiratory Review 29 (155), 1-10 (2020).

31.   Chigurupati, R. et al., Considerations for Oral and Maxillofacial Surgeons in

COVID-19 era: Can we sustain the solutions to keep our patients and healthcare personnel

safe? Journal of Oral and Maxillofacial Surgery (2020).

32.   Huang, C. et al., Clinical features of patients infected with 2019 novel coronavirus

in Wuhan, China. The Lancet 395, 497-506 (2020).

33.   Ministry of Health, L. a. W., Status of Designation of Class II Designated Medical

Institutions for Infectious Diseases, Available at

https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou15/02-02-01.html (2019).

34.   Haeck, J. D., Dongelmans, D. A. & Schultz, M. J., in JAMA - Journal of the

American Medical Association (2012), Vol. 307, p. 454.

35.   Brodie, D. & Bacchetta, M., Extracorporeal membrane oxygenation for ARDS in

adults. New England Journal of Medicine 365 (20), 1905-1914 (2011).

36.   Japanese Society of Respiratory Care Medicine, ECMO project, Available at

http://square.umin.ac.jp/jrcm/contents/ecmo/index.html.

37.   Statististics Bureau of Japan, Population statistics on 2019, Available at

https://www.stat.go.jp/data/jinsui/2019np/index.html (2020).

38.   Zhou, F. et al., Clinical course and risk factors for mortality of adult inpatients with

COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395 (10229), 1054-

1062 (2020).

39.   Richardson, S. et al., Presenting Characteristics, Comorbidities, and Outcomes

Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA

323 (20), 2052 (2020).

40.   Guan, W. et al., Clinical characteristics of coronavirus disease 2019 in China. New

England Journal of Medicine 382 (18), 1708-1720 (2020).

41.   The Japanese Sciety of Intensive Care Medicine, Available at

https://www.jsicm.org/news/news200514.html.

42.   Lois, M., in Journal of Critical Care (W.B. Saunders, 2014), Vol. 29, pp. 1121-1122.

43.   Gutsche, J. T. & Kohl, B. A., in Critical Care Medicine (Crit Care Med, 2007), Vol.

35.

44.   Hokkaido Government, Declarations a State of Emergency in Hokkaido, Available

at http://www.pref.hokkaido.lg.jp/ss/tkk/koronasengen.htm.

45.   Takeda, S. et al., Extracorporeal membrane oxygenation for 2009 influenza

A(H1N1) severe respiratory failure in Japan. Journal of Anesthesia 26 (5), 650-657 (2012).

46.   Checkley, W., in JAMA - Journal of the American Medical Association (2011), Vol.

306, pp. 1703-1704.

47.   Noah, M. A. et al., Referral to an extracorporeal membrane oxygenation center and

mortality among patients with severe 2009 influenza A(H1N1). JAMA - Journal of the

American Medical Association 306 (15), 1659-1668 (2011).

48.   Laudi, S., Busch, T. & Kaisers, U., Extracorporeal membrane oxygenation for

ARDS due to 2009 influenza A(H1N1). JAMA 303 (10), 941; author reply 942 (2010).

49.   Davies, A. R. et al., Extracorporeal membrane oxygenation for 2009 influenza

A(H1N1) acute respiratory distress syndrome. JAMA - Journal of the American Medical

Association 302 (17), 1888-1895 (2009).

50.   Peek, G. J. et al., Efficacy and economic assessment of conventional ventilatory

support versus extracorporeal membrane oxygenation for severe adult respiratory failure

(CESAR): a multicentre randomised controlled trial. The Lancet 374 (9698), 1351-1363

(2009).

51.   Japan ECMOnet for COVID-19: Telephone consultations for cases with severe

respiratory failure caused by COVID-19. Journal of Intensive Care 8 (1) (2020).

52.   Nationwide system to centralize decisions around ECMO use for severe COVID-19

pneumonia in Japan (Special Correspondence). Journal of Intensive Care 8 (1), 29 (2020).